Present and future of PI3K pathway inhibition in cancer: Perspectives and limitations

Current Medicinal Chemistry

Volumn 18, Issue 18, 2011, Pages 2674-2685

  Ciraolo, E ^a   Morello, F ^a   Hirsch, E ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

Akt; Cancer; Enzyme inhibitors; mTOR; PI3K

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 2 (1H INDAZOL 4 YL) 6 (4 METHANESULFONYL 1 PIPERAZINYLMETHYL) 4 MORPHOLINOTHIENO[3,2 D]PYRIMIDINE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; 5 (6 QUINOXALINYLMETHYLENE) 2,4 THIAZOLIDINEDIONE; 9 (1 ANILINOETHYL) 7 METHYL 2 MORPHOLINOPYRIDO[1,2 A]PYRIMIDIN 4 ONE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; CAL 101; DOCETAXEL; DOXORUBICIN; GDC 0980; GSK 2126458; ISOENZYME; MAMMALIAN TARGET OF RAPAMYCIN; NVP BKM 120; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PIK 75; TRASTUZUMAB; UNCLASSIFIED DRUG; VINCRISTINE; XL 147; XL 765;

ABDOMINAL DISCOMFORT; ACUTE GRANULOCYTIC LEUKEMIA; AMINOTRANSFERASE BLOOD LEVEL; ARTERY THROMBOSIS; ARTICLE; BREAST CANCER; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; DIARRHEA; DRUG MECHANISM; DYSGEUSIA; ENDOMETRIUM CANCER; ENZYME INHIBITION; FATIGUE; GLIOBLASTOMA; HUMAN; INSULIN BLOOD LEVEL; LUNG CANCER; LYMPHOMA; MULTIPLE MYELOMA; NAUSEA; NEOPLASM; NONHODGKIN LYMPHOMA; OVARY CANCER; PERIPHERAL EDEMA; PROTEIN TARGETING; RASH; SIDE EFFECT; TUMOR GROWTH; VOMITING;

ANTINEOPLASTIC AGENTS; CLINICAL MEDICINE; HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; TOR SERINE-THREONINE KINASES;

EID: 79959334964     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711796011193     Document Type: Article

References (149)

1. Hirsch, E.; Costa, C.; Ciraolo, E. Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. J. Endocrinol. 2007, 194(2), 243-256. (Pubitemid 47249663)
2. Katso, R.; Okkenhaug, K.; Ahmadi, K.; White, S.; Timms, J.; Waterfield, M. D. Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell. Dev. Biol. 2001, 17, 615-675. (Pubitemid 33096187)
3. Schwindinger, W. F.; Robishaw, J. D. Heterotrimeric G-protein betagammadimers in growth and differentiation. Oncogene. 2001, 20(13), 1653-1660. (Pubitemid 32336854)
4. Astle, M. V.; Horan, K. A.; Ooms, L. M.; Mitchell, C. A. The inositol polyphosphate 5-phosphatases: traffic controllers, waistline watchers and tumour suppressors? Biochem. Soc. Symp. 2007(74), 161-181.
5. Ooms, L. M.; Horan, K. A.; Rahman, P.; Seaton, G.; Gurung, R.; Kethesparan, D. S.; Mitchell, C. A. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. Biochem. J. 2009, 419(1), 29-49.
6. Ma, K.; Cheung, S. M.; Marshall, A. J.; Duronio, V. PI (3, 4, 5) P3 and PI (3, 4) P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI (3, 4) P2 levels determine PKB activity. Cell Signal. 2008, 20(4), 684-694.
7. Scheid, M. P.; Huber, M.; Damen, J. E.; Hughes, M.; Kang, V.; Neilsen, P.; Prestwich, G. D.; Krystal, G.; Duronio, V. Phosphatidylinositol (3, 4, 5) P3 is essential but not sufficient for protein kinase B (PKB) activation; phosphatidylinositol (3, 4) P2 is required for PKB phosphorylation at Ser-473: studies using cells from SH2-containing inositol-5-phosphatase knockout mice. J. Biol. Chem. 2002, 277(11), 9027-9035. (Pubitemid 34952976)
8. Guertin, D. A.; Sabatini, D. M. Defining the role of mTOR in cancer. Cancer Cell. 2007, 12(1), 9-22. (Pubitemid 47001784)
9. Sarbassov, D. D.; Guertin, D. A.; Ali, S. M.; Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005, 307(5712), 1098-1101. (Pubitemid 40262113)
10. Gymnopoulos, M.; Elsliger, M. A.; Vogt, P. K. Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(13), 5569-5574. (Pubitemid 47175721)
11. Samuels, Y.; Wang, Z.; Bardelli, A.; Silliman, N.; Ptak, J.; Szabo, S.; Yan, H.; Gazdar, A.; Powell, S. M.; Riggins, G. J.; Willson, J. K.; Markowitz, S.; Kinzler, K. W.; Vogelstein, B.; Velculescu, V. E. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004, 304(5670), 554. (Pubitemid 38541907)
12. Zhao, L.; Vogt, P. K. Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(7), 2652-2657. (Pubitemid 351520568)
13. Chaussade, C.; Cho, K.; Mawson, C.; Rewcastle, G. W.; Shepherd, P. R. Functional differences between two classes of oncogenic mutation in the PIK3CA gene. Biochem. Biophys. Res. Commun. 2009, 381(4), 577-581.
14. Bader, A. G.; Kang, S.; Vogt, P. K. Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(5), 1475-1479. (Pubitemid 43191190)
15. Morrow, C. J.; Gray, A.; Dive, C. Comparison of phosphatidylinositol-3- kinase signalling within a panel of human colorectal cancer cell lines with mutant or wild-type PIK3CA. FEBS Lett. 2005, 579(23), 5123-5128. (Pubitemid 41318079)
16. Vasudevan, K. M.; Barbie, D. A.; Davies, M. A.; Rabinovsky, R.; McNear, C. J.; Kim, J. J.; Hennessy, B. T.; Tseng, H.; Pochanard, P.; Kim, S. Y.; Dunn, I. F.; Schinzel, A. C.; Sandy, P.; Hoersch, S.; Sheng, Q.; Gupta, P. B.; Boehm, J. S.; Reiling, J. H.; Silver, S.; Lu, Y.; Stemke-Hale, K.; Dutta, B.; Joy, C.; Sahin, A. A.; Gonzalez-Angulo, A. M.; Lluch, A.; Rameh, L. E.; Jacks, T.; Root, D. E.; Lander, E. S.; Mills, G. B.; Hahn, W. C.; Sellers, W. R.; Garraway, L. A. AKT-Independent Signaling Downstream of Oncogenic PIK3CA Mutations in Human Cancer. Cancer Cell. 2009, 16(1), 21-32.
17. Velasco, A.; Bussaglia, E.; Pallares, J.; Dolcet, X.; Llobet, D.; Encinas, M.; Llecha, N.; Palacios, J.; Prat, J.; Matias-Guiu, X. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum. Pathol. 2006, 37(11), 1465-1472. (Pubitemid 44584324)
18. Silvestris, N.; Tommasi, S.; Petriella, D.; Santini, D.; Fistola, E.; Russo, A.; Numico, G.; Tonini, G.; Maiello, E.; Colucci, G. The dark side of the moon: the PI3K/PTEN/AKT pathway in colorectal carcinoma. Oncology. 2009, 77. Suppl. 1, 69-74.
19. Bachman, K. E.; Argani, P.; Samuels, Y.; Silliman, N.; Ptak, J.; Szabo, S.; Konishi, H.; Karakas, B.; Blair, B. G.; Lin, C.; Peters, B. A.; Velculescu, V. E.; Park, B. H. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol. Ther. 2004, 3(8), 772-775. (Pubitemid 41351083)
20. Saal, L. H.; Holm, K.; Maurer, M.; Memeo, L.; Su, T.; Wang, X.; Yu, J. S.; Malmstrom, P. O.; Mansukhani, M.; Enoksson, J.; Hibshoosh, H.; Borg, A.; Parsons, R. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 2005, 65(7), 2554-2559. (Pubitemid 40490050)
21. Knobbe, C. B.; Reifenberger, G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain. Pathol. 2003, 13(4), 507-518. (Pubitemid 37420695)
22. Benistant, C.; Chapuis, H.; Roche, S. A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene. 2000, 19(44), 5083-5090.
23. Kang, S.; Denley, A.; Vanhaesebroeck, B.; Vogt, P. K. Oncogenic transformation induced by the p110beta,-gamma, and-delta isoforms of class I phosphoinositide 3-kinase. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(5), 1289-1294. (Pubitemid 43191158)
24. Lee, S. H.; Poulogiannis, G.; Pyne, S.; Jia, S.; Zou, L.; Signoretti, S.; Loda, M.; Cantley, L. C.; Roberts, T. M. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(24), 11002-11007.
25. Link, W.; Rosado, A.; Fominaya, J.; Thomas, J. E.; Carnero, A. Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J. Cell. Biochem. 2005, 95(5), 979-989. (Pubitemid 41420145)
26. Edling, C. E.; Selvaggi, F.; Buus, R.; Maffucci, T.; Di Sebastiano, P.; Friess, H.; Innocenti, P.; Kocher, H. M.; Falasca, M. Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin. Cancer Res. 2010, 16(20), 4928-4937.
27. Carvalho, S.; Milanezi, F.; Costa, J. L.; Amendoeira, I.; Schmitt, F. PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch. 2010, 456(3), 235-243.
28. Hill, K. M.; Kalifa, S.; Das, J. R.; Bhatti, T.; Gay, M.; Williams, D.; Taliferro-Smith, L.; De Marzo, A. M. The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells. Prostate. 2010, 70(7), 755-764.
29. Ciraolo, E.; Iezzi, M.; Marone, R.; Marengo, S.; Curcio, C.; Costa, C.; Azzolino, O.; Gonella, C.; Rubinetto, C.; Wu, H.; Dastru, W.; Martin, E. L.; Silengo, L.; Altruda, F.; Turco, E.; Lanzetti, L.; Musiani, P.; Ruckle, T.; Rommel, C.; Backer, J. M.; Forni, G.; Wymann, M. P.; Hirsch, E. Phosphoinositide 3-kinase p110beta activity: key role in metabolism and mammary gland cancer but not development. Sci. Signal. 2008, 1(36), ra3.
30. Jia, S.; Liu, Z.; Zhang, S.; Liu, P.; Zhang, L.; Lee, S. H.; Zhang, J.; Signoretti, S.; Loda, M.; Roberts, T. M.; Zhao, J. J. Essential roles of PI (3) K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008, 454(7205), 776-779.
31. Wee, S.; Wiederschain, D.; Maira, S. M.; Loo, A.; Miller, C.; De Beaumont, R.; Stegmeier, F.; Yao, Y. M.; Lengauer, C. PTEN-deficient cancers depend on PIK3CB. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(35), 13057-13062.
32. Sattler, M.; Verma, S.; Byrne, C. H.; Shrikhande, G.; Winkler, T.; Algate, P. A.; Rohrschneider, L. R.; Griffin, J. D. BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis. Mol. Cell. Biol. 1999, 19(11), 7473-7480. (Pubitemid 29493410)
33. Fukuda, R.; Hayashi, A.; Utsunomiya, A.; Nukada, Y.; Fukui, R.; Itoh, K.; Tezuka, K.; Ohashi, K.; Mizuno, K.; Sakamoto, M.; Hamanoue, M.; Tsuji, T. Alteration of phosphatidylinositol 3-kinase cascade in the multilobulated nuclear formation of adult T cell leukemia/lymphoma (ATLL). Proc. Natl. Acad. Sci. U. S. A. 2005, 102(42), 15213-15218. (Pubitemid 41513361)
34. Horn, S.; Endl, E.; Fehse, B.; Weck, M. M.; Mayr, G. W.; Jucker, M. Restoration of SHIP activity in a human leukemia cell line downregulates constitutively activated phosphatidylinositol 3-kinase/Akt/GSK-3beta signaling and leads to an increased transit time through the G1 phase of the cell cycle. Leukemia. 2004, 18(11), 1839-1849. (Pubitemid 39530015)
35. Prasad, N. K.; Tandon, M.; Badve, S.; Snyder, P. W.; Nakshatri, H. Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis. 2008, 29(1), 25-34. (Pubitemid 351201738)
36. Chow, K. U.; Nowak, D.; Kim, S. Z.; Schneider, B.; Komor, M.; Boehrer, S.; Mitrou, P. S.; Hoelzer, D.; Weidmann, E.; Hofmann, W. K. In vivo drugresponse in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling. Pharmacol. Res. 2006, 53(1), 49-61. (Pubitemid 41622216)
37. Quade, B. J.; Wang, T. Y.; Sornberger, K.; Dal Cin, P.; Mutter, G. L.; Morton, C. C. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer. 2004, 40(2), 97-108. (Pubitemid 38579878)
38. Akada, M.; Crnogorac-Jurcevic, T.; Lattimore, S.; Mahon, P.; Lopes, R.; Sunamura, M.; Matsuno, S.; Lemoine, N. R. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin. Cancer Res. 2005, 11(8), 3094-3101. (Pubitemid 40525216)
39. Kim, B.; Bang, S.; Lee, S.; Kim, S.; Jung, Y.; Lee, C.; Choi, K.; Lee, S. G.; Lee, K.; Lee, Y.; Kim, S. S.; Yeom, Y. I.; Kim, Y. S.; Yoo, H. S.; Song, K.; Lee, I. Expression profiling and subtype-specific expression of stomach cancer. Cancer Res. 2003, 63(23), 8248-8255. (Pubitemid 37549475)
40. Ramaswamy, S.; Ross, K. N.; Lander, E. S.; Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nat. Genet. 2003, 33(1), 49-54. (Pubitemid 36068681)
41. Jaiswal, B. S.; Janakiraman, V.; Kljavin, N. M.; Chaudhuri, S.; Stern, H. M.; Wang, W.; Kan, Z.; Dbouk, H. A.; Peters, B. A.; Waring, P.; Dela Vega, T.; Kenski, D. M.; Bowman, K. K.; Lorenzo, M.; Li, H.; Wu, J.; Modrusan, Z.; Stinson, J.; Eby, M.; Yue, P.; Kaminker, J. S.; de Sauvage, F. J.; Backer, J. M.; Seshagiri, S. Somatic mutations in p85alpha promote tumorigenesis through class IA PI3K activation. Cancer Cell. 2009, 16(6), 463-474.
42. Berenjeno, I. M.; Vanhaesebroeck, B. PI3K regulatory subunits lose control in cancer. Cancer Cell. 2009, 16(6), 449-450.
43. C. G. A. N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008, 455(7216), 1061-1068.
44. Sun, M.; Hillmann, P.; Hofmann, B. T.; Hart, J. R.; Vogt, P. K. Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(35), 15547-15552.
45. Wagner, A. J.; Von Hoff, D. H.; LoRusso, P. M.; Tibes, R.; Mazina, K. E.; Ware, J. A.; Yan, Y.; Derynck, M. K.; Demetri, G. D. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J. Clin. Oncol. 2009, 27(15), 3501.
46. Folkes, A. J.; Ahmadi, K.; Alderton, W. K.; Alix, S.; Baker, S. J.; Box, G.; Chuckowree, I. S.; Clarke, P. A.; Depledge, P.; Eccles, S. A.; Friedman, L. S.; Hayes, A.; Hancox, T. C.; Kugendradas, A.; Lensun, L.; Moore, P.; Olivero, A. G.; Pang, J.; Patel, S.; Pergl-Wilson, G. H.; Raynaud, F. I.; Robson, A.; Saghir, N.; Salphati, L.; Sohal, S.; Ultsch, M. H.; Valenti, M.; Wallweber, H. J.; Wan, N. C.; Wiesmann, C.; Workman, P.; Zhyvoloup, A.; Zvelebil, M. J.; Shuttleworth, S. J. The identification of 2-(1H-indazol-4-yl)-6-(4- methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3, 2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem. 2008, 51(18), 5522-5532.
47. Edgar, K. A.; Wallin, J. J.; Berry, M.; Lee, L. B.; Prior, W. W.; Sampath, D.; Friedman, L. S.; Belvin, M. Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors. Cancer Res. 2010, 70(3), 1164-1172.
48. Salphati, L.; Wong, H.; Belvin, M.; Bradford, D.; Edgar, K. A.; Prior, W. W.; Sampath, D.; Wallin, J. J. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941. Drug. Metab. Dispos. 2010, 38(9), 1436-1442.
49. Sos, M. L.; Fischer, S.; Ullrich, R.; Peifer, M.; Heuckmann, J. M.; Koker, M.; Heynck, S.; Stuckrath, I.; Weiss, J.; Fischer, F.; Michel, K.; Goel, A.; Regales, L.; Politi, K. A.; Perera, S.; Getlik, M.; Heukamp, L. C.; Ansen, S.; Zander, T.; Beroukhim, R.; Kashkar, H.; Shokat, K. M.; Sellers, W. R.; Rauh, D.; Orr, C.; Hoeflich, K. P.; Friedman, L.; Wong, K. K.; Pao, W.; Thomas, R. K. Identifying genotype-dependent efficacy of single and combined PI3K-and MAPK-pathway inhibition in cancer. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(43), 18351-18356.
50. Yao, E.; Zhou, W.; Lee-Hoeflich, S. T.; Truong, T.; Haverty, P. M.; Eastham-Anderson, J.; Lewin-Koh, N.; Gunter, B.; Belvin, M.; Murray, L. J.; Friedman, L. S.; Sliwkowski, M. X.; Hoeflich, K. P. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab. Clin. Cancer Res. 2009, 15(12), 4147-4156.
51. Hoeflich, K. P.; Herter, S.; Tien, J.; Wong, L.; Berry, L.; Chan, J.; O'Brien, C.; Modrusan, Z.; Seshagiri, S.; Lackner, M.; Stern, H.; Choo, E.; Murray, L.; Friedman, L. S.; Belvin, M. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 2009, 69(7), 3042-3051.
52. Laird, D. XL765 targets tumor growth, survival, and angiogenesis in preclinical models by dual inhibition of PI3K and mTOR. 2007, AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
53. Carnero, A. Novel inhibitors of the PI3K family. Expert Opin. Investig. Drugs. 2009, 18(9), 1265-1277.
54. Garcia-Echeverria, C. Protein and lipid kinase inhibitors as targeted anticancer agents of the Ras/Raf/MEK and PI3K/PKB pathways. Purinergic Signal. 2009, 5(1), 117-125.
55. Shapiro, G.; Kwak, E.; Baselga, J.; Rodon, J.; Scheffold, C.; Laird, A. D.; Bedell, C.; Edelman, G. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J. Clin. Oncol. 2009, 27(15), 3500.
56. Ihle, N. T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M. I.; Paine-Murrieta, G.; Minion, D. J.; Halter, R. J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther. 2004, 3(7), 763-772. (Pubitemid 39193758)
57. Ihle, N. T.; Paine-Murrieta, G.; Berggren, M. I.; Baker, A.; Tate, W. R.; Wipf, P.; Abraham, R. T.; Kirkpatrick, D. L.; Powis, G. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol. Cancer Ther. 2005, 4(9), 1349-1357.
58. Howes, A. L.; Chiang, G. G.; Lang, E. S.; Ho, C. B.; Powis, G.; Vuori, K.; Abraham, R. T. The phosphatidylinositol 3-kinase inhibitor, PX-866, is a potent inhibitor of cancer cell motility and growth in three-dimensional cultures. Mol. Cancer Ther. 2007, 6(9), 2505-2514. (Pubitemid 47480416)
59. Jimeno, A.; Hong, D. S.; Hecker, S.; Clement, R.; Kurzrock, R.; Pestano, L. A.; Hiscox, A.; Leos, R. A.; Kirkpatrick, D. L.; Eckhardt, S. G.; Herbst, R. S. Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. J. Clin. Oncol. 2009, 27(15), 3542.
60. Markman, B.; Atzori, F.; Perez-Garcia, J.; Tabernero, J.; Baselga, J. Status of PI3K inhibition and biomarker development in cancer therapeutics. Annals of Oncology. 2010, 21(4), 683-691.
61. Pacold, M. E.; Suire, S.; Perisic, O.; Lara-Gonzalez, S.; Davis, C. T.; Walker, E. H.; Hawkins, P. T.; Stephens, L.; Eccleston, J. F.; Williams, R. L. Crystal structure and functional analysis of Ras binding to its effector phosphoinositide 3-kinase gamma. Cell. 2000, 103(6), 931-943.
62. Huang, C. H.; Mandelker, D.; Schmidt-Kittler, O.; Samuels, Y.; Velculescu, V. E.; Kinzler, K. W.; Vogelstein, B.; Gabelli, S. B.; Amzel, L. M. The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations. Science. 2007, 318(5857), 1744-1748. (Pubitemid 350274378)
63. Berndt, A.; Miller, S.; Williams, O.; Le, D. D.; Houseman, B. T.; Pacold, J. I.; Gorrec, F.; Hon, W. C.; Liu, Y.; Rommel, C.; Gaillard, P.; Ruckle, T.; Schwarz, M. K.; Shokat, K. M.; Shaw, J. P.; Williams, R. L. The p110delta structure: mechanisms for selectivity and potency of new PI (3) K inhibitors. Nat. Chem. Biol. 2010, 6(3), 244.
64. Brown, J.; Byrd, J.; Furman, R.; Flinn, I.; Benson, D.; Coutre, S.; Kahl, B.; Wagner-Johnston, N.; Spurgeon, S.; Pratz, K.; Giese, N.; Yu, O. A. Clinical activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase p110delta, in patients with B-cell malignancies. J. Clin. Oncol. 2009, 27(15), 3543.
65. Herman, S. E.; Gordon, A. L.; Wagner, A. J.; Heerema, N. A.; Zhao, W.; Flynn, J. M.; Jones, J.; Andritsos, L.; Puri, K. D.; Lannutti, B. J.; Giese, N. A.; Zhang, X.; Wei, L.; Byrd, J. C.; Johnson, A. J. The phosphatidylinositol 3-kinase-{delta} inhibitor CAL-101 demonstrates promising pre-clinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010.
66. Ikeda, H.; Hideshima, T.; Fulciniti, M.; Perrone, G.; Miura, N.; Yasui, H.; Okawa, Y.; Kiziltepe, T.; Santo, L.; Vallet, S.; Cristea, D.; Calabrese, E.; Gorgun, G.; Raje, N. S.; Richardson, P.; Munshi, N. C.; Lannutti, B. J.; Puri, K. D.; Giese, N. A.; Anderson, K. C. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010, 116(9), 1460-1468.
67. Harrington, L. S.; Findlay, G. M.; Gray, A.; Tolkacheva, T.; Wigfield, S.; Rebholz, H.; Barnett, J.; Leslie, N. R.; Cheng, S.; Shepherd, P. R.; Gout, I.; Downes, C. P.; Lamb, R. F. The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell. Biol. 2004, 166(2), 213-223. (Pubitemid 38988774)
68. Um, S. H.; Frigerio, F.; Watanabe, M.; Picard, F.; Joaquin, M.; Sticker, M.; Fumagalli, S.; Allegrini, P. R.; Kozma, S. C.; Auwerx, J.; Thomas, G. Absence of S6K1 protects against age-and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004, 431(7005), 200-205. (Pubitemid 39243474)
69. Carracedo, A.; Ma, L.; Teruya-Feldstein, J.; Rojo, F.; Salmena, L.; Alimonti, A.; Egia, A.; Sasaki, A. T.; Thomas, G.; Kozma, S. C.; Papa, A.; Nardella, C.; Cantley, L. C.; Baselga, J.; Pandolfi, P. P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118(9), 3065-3074.
70. Veilleux, A.; Houde, V. P.; Bellmann, K.; Marette, A. Chronic inhibition of the mTORC1/S6K1 pathway increases insulin-induced PI3K activity but inhibits Akt2 and glucose transport stimulation in 3T3-L1 adipocytes. Mol. Endocrinol. 2010, 24(4), 766-778.
71. Garlich, J. R.; De, P.; Dey, N.; Su, J. D.; Peng, X.; Miller, A.; Murali, R.; Lu, Y.; Mills, G. B.; Kundra, V.; Shu, H. K.; Peng, Q.; Durden, D. L. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008, 68(1), 206-215. (Pubitemid 351380122)
72. Ozbay, T.; Durden, D. L.; Liu, T.; O'Regan, R. M.; Nahta, R. In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother. Pharmacol. 2009, 65(4), 697-706.
73. Chiorean, E. G.; Mahadevan, D.; Harris, W. B.; Von Hoff, D. D.; Younger, A. E.; Rensvold, D. M.; Shelton, C. F.; Hennessy, B. T.; Garlich, J. R.; Ramanathan, R. K. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J. Clin. Oncol. 2009, 27, 15s.
74. Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P. J.; Valero, V.; Guzman, M.; Botero, M. L.; Llonch, E.; Atzori, F.; Di Cosimo, S.; Maira, M.; Garcia-Echeverria, C.; Parra, J. L.; Arribas, J.; Baselga, J. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008, 68(19), 8022-8030.
75. Manara, M. C.; Nicoletti, G.; Zambelli, D.; Ventura, S.; Guerzoni, C.; Landuzzi, L.; Lollini, P. L.; Maira, S. M.; Garcia-Echeverria, C.; Mercuri, M.; Picci, P.; Scotlandi, K. NVP-BEZ235 as a new therapeutic option for sarcomas. Clin. Cancer Res. 2010, 16(2), 530-540.
76. Bhende, P. M.; Park, S. I.; Lim, M. S.; Dittmer, D. P.; Damania, B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia. 2010.
77. LoRusso, P.; Markman, B.; Tabernero, J.; Shazer, R.; Nguyen, L.; Heath, E.; Patnaik, A.; Papadopoulos, K. A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. Journal. of. Clinical. Oncology. 2009, 27(15), 3502.
78. Gwak, H. S.; Shingu, T.; Chumbalkar, V.; Hwang, Y. H.; Dejournett, R.; Latha, K.; Koul, D.; Alfred Yung, W. K.; Powis, G.; Farrell, N. P.; Bogler, O. Combined action of the dinuclear platinum compound BBR3610 with the PI3-K inhibitor PX-866 in glioblastoma. Int. J. Cancer. 2011, 128(4), 787-796.
79. Martin-Fernandez, C.; Bales, J.; Hodgkinson, C.; Welman, A.; Welham, M. J.; Dive, C.; Morrow, C. J. Blocking phosphoinositide 3-kinase activity in colorectal cancer cells reduces proliferation but does not increase apoptosis alone or in combination with cytotoxic drugs. Mol. Cancer Res. 2009, 7(6), 955-965.
80. Lee, J. T., Jr.; Steelman, L. S.; McCubrey, J. A. Phosphatidylinositol 3'-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res. 2004, 64(22), 8397-8404. (Pubitemid 39491779)
81. Kim, D.; Dan, H. C.; Park, S.; Yang, L.; Liu, Q.; Kaneko, S.; Ning, J.; He, L.; Yang, H.; Sun, M.; Nicosia, S. V.; Cheng, J. Q. AKT/PKB signaling mechanisms in cancer and chemoresistance. Front. Biosci. 2005, 10, 975-987.
82. Huang, W. C.; Hung, M. C. Induction of Akt activity by chemotherapy confers acquired resistance. J. Formos. Med. Assoc. 2009, 108(3), 180-194.
83. Poh, T. W.; Pervaiz, S. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway. Cancer Res. 2005, 65(14), 6264-6274. (Pubitemid 40994412)
84. Wallin, J. J.; Guan, J.; Prior, W. W.; Edgar, K. A.; Kassees, R.; Sampath, D.; Belvin, M.; Friedman, L. S. Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer. Sci. Transl. Med. 2010, 2(48), 48ra66.
85. Lempiainen, H.; Halazonetis, T. D. Emerging common themes in regulation of PIKKs and PI3Ks. EMBO J. 2009, 28(20), 3067-3073.
86. Gharbi, S. I.; Zvelebil, M. J.; Shuttleworth, S. J.; Hancox, T.; Saghir, N.; Timms, J. F.; Waterfield, M. D. Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 2007, 404(1), 15-21. (Pubitemid 46788080)
87. Kong, D.; Yaguchi, S.; Yamori, T. Effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor, on DNA-dependent protein kinase. Biol. Pharm. Bull. 2009, 32(2), 297-300.
88. Maira, S. M.; Stauffer, F.; Brueggen, J.; Furet, P.; Schnell, C.; Fritsch, C.; Brachmann, S.; Chene, P.; De Pover, A.; Schoemaker, K.; Fabbro, D.; Gabriel, D.; Simonen, M.; Murphy, L.; Finan, P.; Sellers, W.; Garcia-Echeverria, C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7(7), 1851-1863.
89. Knight, S. D.; Adams, N. D.; Burgess, J. L.; Chaudhari, A. M.; Darcy, M. G.; Donatelli, C. A.; Luengo, J. I.; Newlander, K. A.; Parrish, C. A.; Ridgers, L. H.; Sarpong, M. A.; Schmidt, S. J.; Van Aller, G. S.; Carson, J. D.; Diamond, M. A.; Elkins, P. A.; Gardiner, C. M.; Garver, E.; Gilbert, S. A.; Gontarek, R. R.; Jackson, J. R.; Kershner, K. L.; Luo, L.; Raha, K.; Sherk, C. S.; Sung, C.-M.; Sutton, D.; Tummino, P. J.; Wegrzyn, R. J.; Auger, K. R.; Dhanak, D. Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin. ACS Med. Chem. Lett. 2010, 1(1), 39-43.
90. Westhoff, M. A.; Kandenwein, J. A.; Karl, S.; Vellanki, S. H.; Braun, V.; Eramo, A.; Antoniadis, G.; Debatin, K. M.; Fulda, S. The pyridinylfuranopyrimidine inhibitor, PI-103, chemosensitizes glioblastoma cells for apoptosis by inhibiting DNA repair. Oncogene. 2009, 28(40), 3586-3596.
91. Fruman, D. A.; Bismuth, G. Fine tuning the immune response with PI3K. Immunological Reviews. 2009, 228(1), 253-272.
92. Ghigo, A.; Damilano, F.; Braccini, L.; Hirsch, E. PI3K inhibition in inflammation: Toward tailored therapies for specific diseases. Bioessays. 2010, 32(3), 185-196.
93. Braccini, L.; Ciraolo, E.; Morello, F.; Lu, X.; Hirsch, E. PI3K signaling: a crossroads of metabolic regulation. Expert Review of Endocrinology & Metabolism. 2009, 4(4), 349-357.
94. Cross, D. A.; Alessi, D. R.; Cohen, P.; Andjelkovich, M.; Hemmings, B. A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995, 378(6559), 785-789. (Pubitemid 26004411)
95. Dickson, L. M.; Rhodes, C. J. Pancreatic beta-cell growth and survival in the onset of type 2 diabetes: a role for protein kinase B in the Akt? Am. J. Physiol. Endocrinol. Metab. 2004, 287(2), E192-198. (Pubitemid 38943882)
96. Pigeau, G. M.; Kolic, J.; Ball, B. J.; Hoppa, M. B.; Wang, Y. W.; Ruckle, T.; Woo, M.; Manning Fox, J. E.; MacDonald, P. E. Insulin granule recruitment and exocytosis is dependent on p110gamma in insulinoma and human betacells. Diabetes. 2009, 58(9), 2084-2092.
97. Taniguchi, C. M.; Kondo, T.; Sajan, M.; Luo, J.; Bronson, R.; Asano, T.; Farese, R.; Cantley, L. C.; Kahn, C. R. Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKClambda/zeta. Cell Metab. 2006, 3(5), 343-353.
98. Foukas, L. C.; Claret, M.; Pearce, W.; Okkenhaug, K.; Meek, S.; Peskett, E.; Sancho, S.; Smith, A. J.; Withers, D. J.; Vanhaesebroeck, B. Critical role for the p110alpha phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature. 2006, 441(7091), 366-370. (Pubitemid 44050203)
99. MacDonald, P. E.; Joseph, J. W.; Yau, D.; Diao, J.; Asghar, Z.; Dai, F.; Oudit, G. Y.; Patel, M. M.; Backx, P. H.; Wheeler, M. B. Impaired glucose-stimulated insulin secretion, enhanced intraperitoneal insulin tolerance, and increased beta-cell mass in mice lacking the p110gamma isoform of phosphoinositide 3-kinase. Endocrinology. 2004, 145(9), 4078-4083. (Pubitemid 39120555)
100. Shepherd, P. R.; Nave, B. T.; Siddle, K. Insulin stimulation of glycogen synthesis and glycogen synthase activity is blocked by wortmannin and rapamycin in 3T3-L1 adipocytes: evidence for the involvement of phosphoinositide 3-kinase and p70 ribosomal protein-S6 kinase. Biochem. J. 1995, 305. (Pt. 1), 25-28.
101. Lee, A. D.; Hansen, P. A.; Holloszy, J. O. Wortmannin inhibits insulinstimulated but not contraction-stimulated glucose transport activity in skeletal muscle. FEBS Lett. 1995, 361(1), 51-54.
102. Knight, Z. A.; Gonzalez, B.; Feldman, M. E.; Zunder, E. R.; Goldenberg, D. D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W. A.; Williams, R. L.; Shokat, K. M. A Pharmacological Map of the PI3-K Family Defines a Role for p110[alpha] in Insulin Signaling. Cell. 2006, 125(4), 733-747.
103. Kim, J. E.; Shepherd, P. R.; Chaussade, C. Investigating the role of class-IA PI 3-kinase isoforms in adipocyte differentiation. Biochem. Biophys. Res. Commun. 2009, 379(4), 830-834.
104. Tups, A.; Anderson, G. M.; Rizwan, M.; Augustine, R. A.; Chaussade, C.; Shepherd, P. R.; Grattan, D. R. Both p110α and p110β Isoforms of Phosphatidylinositol 3-OH-Kinase are Required for Insulin Signalling in the Hypothalamus. Journal of Neuroendocrinology. 2010, 22(6), 534-542.
105. Oudit, G. Y.; Penninger, J. M. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc. Res. 2009, 82(2), 250-260.
106. Morello, F.; Perino, A.; Hirsch, E. Phosphoinositide 3-kinase signalling in the vascular system. Cardiovasc. Res. 2009, 82(2), 261-271.
107. Crackower, M. A.; Oudit, G. Y.; Kozieradzki, I.; Sarao, R.; Sun, H.; Sasaki, T.; Hirsch, E.; Suzuki, A.; Shioi, T.; Irie-Sasaki, J.; Sah, R.; Cheng, H. Y.; Rybin, V. O.; Lembo, G.; Fratta, L.; Oliveira-dos-Santos, A. J.; Benovic, J. L.; Kahn, C. R.; Izumo, S.; Steinberg, S. F.; Wymann, M. P.; Backx, P. H.; Penninger, J. M. Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways. Cell 2002, 110(6), 737-749. (Pubitemid 35283963)
108. McMullen, J. R.; Shioi, T.; Huang, W. Y.; Zhang, L.; Tarnavski, O.; Bisping, E.; Schinke, M.; Kong, S.; Sherwood, M. C.; Brown, J.; Riggi, L.; Kang, P. M.; Izumo, S. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase (p110alpha) pathway. J. Biol. Chem. 2004, 279(6), 4782-4793. (Pubitemid 38199073)
109. McMullen, J. R.; Shioi, T.; Zhang, L.; Tarnavski, O.; Sherwood, M. C.; Kang, P. M.; Izumo, S. Phosphoinositide 3-kinase (p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(21), 12355-12360. (Pubitemid 37271564)
110. O'Neill, B. T.; Kim, J.; Wende, A. R.; Theobald, H. A.; Tuinei, J.; Buchanan, J.; Guo, A.; Zaha, V. G.; Davis, D. K.; Schell, J. C.; Boudina, S.; Wayment, B.; Litwin, S. E.; Shioi, T.; Izumo, S.; Birnbaum, M. J.; Abel, E. D. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab. 2007, 6(4), 294-306. (Pubitemid 47450187)
111. Zhang, D.; Contu, R.; Latronico, M. V.; Zhang, J.; Rizzi, R.; Catalucci, D.; Miyamoto, S.; Huang, K.; Ceci, M.; Gu, Y.; Dalton, N. D.; Peterson, K. L.; Guan, K. L.; Brown, J. H.; Chen, J.; Sonenberg, N.; Condorelli, G. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 2010, 120(8), 2805-2816.
112. Sun, H.; Kerfant, B. G.; Zhao, D.; Trivieri, M. G.; Oudit, G. Y.; Penninger, J. M.; Backx, P. H. Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling. Circ. Res. 2006, 98(11), 1390-1397. (Pubitemid 43948063)
113. Shioi, T.; Kang, P. M.; Douglas, P. S.; Hampe, J.; Yballe, C. M.; Lawitts, J.; Cantley, L. C.; Izumo, S. The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO. J. 2000, 19(11), 2537-2548. (Pubitemid 30323543)
114. McMullen, J. R.; Amirahmadi, F.; Woodcock, E. A.; Schinke-Braun, M.; Bouwman, R. D.; Hewitt, K. A.; Mollica, J. P.; Zhang, L.; Zhang, Y.; Shioi, T.; Buerger, A.; Izumo, S.; Jay, P. Y.; Jennings, G. L. Protective effects of exercise and phosphoinositide 3-kinase (p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(2), 612-617. (Pubitemid 46123073)
115. Lin, R. C.; Weeks, K. L.; Gao, X. M.; Williams, R. B.; Bernardo, B. C.;
116. Canobbio, I.; Stefanini, L.; Cipolla, L.; Ciraolo, E.; Gruppi, C.; Balduini, C.; Hirsch, E.; Torti, M. Genetic evidence for a predominant role of PI3K{beta} catalytic activity in ITAM-and integrin-mediated signaling in platelets. Blood. 2009, 114(10), 2193-2196.
117. Hirsch, E.; Bosco, O.; Tropel, P.; Laffargue, M.; Calvez, R.; Altruda, F.; Wymann, M. P.; Montrucchio, G. Resistance to thromboembolism in PI3Kg deficient mice. FASEB J. 2001, 15(11), 2019-2021.
118. Lian, L.; Wang, Y.; Draznin, J.; Eslin, D.; Bennett, J. S.; Poncz, M.; Wu, D.; Abrams, C. S. The relative role of PLC{beta} and PI3K{gamma} in platelet activation. Blood. 2005, 106(1), 110-117. (Pubitemid 40967181)
119. Martin, V.; Guillermet-Guibert, J.; Chicanne, G.; Cabou, C.; Jandrot-Perrus, M.; Plantavid, M.; Vanhaesebroeck, B.; Payrastre, B.; Gratacap, M.-P. Deletion of the p110{beta} isoform of phosphoinositide 3-kinase in platelets reveals its central role in Akt activation and thrombus formation in vitro and in vivo. Blood. 2010, 115(10), 2008-2013.
120. Jackson, S. P.; Schoenwaelder, S. M.; Goncalves, I.; Nesbitt, W. S.; Yap, C. L.; Wright, C. E.; Kenche, V.; Anderson, K. E.; Dopheide, S. M.; Yuan, Y.; Sturgeon, S. A.; Prabaharan, H.; Thompson, P. E.; Smith, G. D.; Shepherd, P. R.; Daniele, N.; Kulkarni, S.; Abbott, B.; Saylik, D.; Jones, C.; Lu, L.; Giuliano, S.; Hughan, S. C.; Angus, J. A.; Robertson, A. D.; Salem, H. H. PI3-kinase p110[beta]: a new target for antithrombotic therapy. Nat. Med. 2005, 11(5), 507-514. (Pubitemid 40685973)
121. Kim, S.; Garcia, A.; Jackson, S. P.; Kunapuli, S. P. Insulin-like growth factor-1 regulates platelet activation through PI3-K{alpha} isoform. Blood. 2007, 110(13), 4206-4213. (Pubitemid 351377784)
122. Kingham, E.; Welham, M. Distinct roles for isoforms of the catalytic subunit of class-IA PI3K in the regulation of behaviour of murine embryonic stem cells. J. Cell. Sci. 2009, 122(13), 2311-2321.
123. Kissel, H.; Timokhina, I.; Hardy, M. P.; Rothschild, G.; Tajima, Y.; Soares, V.; Angeles, M.; Whitlow, S. R.; Manova, K.; Besmer, P. Point mutation in Kit receptor tyrosine kinase reveals essential roles for Kit signaling in spermatogenesis and oogenesis without affecting other Kit responses. EMBO J. 2000, 19(6), 1312-1326. (Pubitemid 30151027)
124. Blume-Jensen, P.; Jiang, G.; Hyman, R.; Lee, K. F.; O'Gorman, S.; Hunter, T. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility. Nat. Genet. 2000, 24(2), 157-162. (Pubitemid 30094716)
125. Reddy, P.; Shen, L.; Ren, C.; Boman, K.; Lundin, E.; Ottander, U.; Lindgren, P.; Liu, Y.-x.; Sun, Q.-y.; Liu, K. Activation of Akt (PKB) and suppression of FKHRL1 in mouse and rat oocytes by stem cell factor during follicular activation and development. Developmental Biology. 2005, 281(2), 160-170. (Pubitemid 40719144)
126. Liu, L.; Rajareddy, S.; Reddy, P.; Du, C.; Jagarlamudi, K.; Shen, Y.; Gunnarsson, D.; Selstam, G.; Boman, K.; Liu, K. Infertility caused by retardation of follicular development in mice with oocyte-specific expression of Foxo3a. Development. 2007, 134(1), 199-209. (Pubitemid 46152720)
127. Liu, K.; Rajareddy, S.; Liu, L.; Jagarlamudi, K.; Boman, K.; Selstam, G.; Reddy, P. Control of mammalian oocyte growth and early follicular development by the oocyte PI3 kinase pathway: New roles for an old timer. Developmental Biology. 2006, 299(1), 1-11. (Pubitemid 44528410)
128. Serve, H.; Hsu, Y. C.; Besmer, P. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J. Biol. Chem. 1994, 269(8), 6026-6030. (Pubitemid 24242986)
129. Lee, J.; Kanatsu-Shinohara, M.; Inoue, K.; Ogonuki, N.; Miki, H.; Toyokuni, S.; Kimura, T.; Nakano, T.; Ogura, A.; Shinohara, T. Akt mediates selfrenewal division of mouse spermatogonial stem cells. Development. 2007, 134(10), 1853-1859. (Pubitemid 46939231)
130. Rothschild, G.; Sottas, C. M.; Kissel, H.; Agosti, V.; Manova, K.; Hardy, M. P.; Besmer, P. A role for kit receptor signaling in Leydig cell steroidogenesis. Biol. Reprod. 2003, 69(3), 925-932. (Pubitemid 37064621)
131. Ciraolo, E.; Morello, F.; Hobbs, R. M.; Wolf, F.; Marone, R.; Iezzi, M.; Lu, X.; Mengozzi, G.; Altruda, F.; Sorba, G.; Guan, K.; Pandolfi, P. P.; Wymann, M. P.; Hirsch, E. Essential role of the p110beta subunit of phosphoinositide 3-OH kinase in male fertility. Mol. Biol. Cell. 2010, 21(5), 704-711.
132. Golden, L. H.; Insogna, K. L. The expanding role of PI3-kinase in bone. Bone. 2004, 34(1), 3-12. (Pubitemid 38142429)
133. Grey, A.; Chaussade, C.; Empson, V.; Lin, J.-M.; Watson, M.; O'Sullivan, S.; Rewcastle, G.; Naot, D.; Cornish, J.; Shepherd, P. Evidence for a role for the p110-[alpha] isoform of PI3K in skeletal function. Biochem. Biophys. Res. Commun. 2010, 391(1), 564-569.
134. Martin, S. K.; Fitter, S.; Bong, L. F.; Drew, J. J.; Gronthos, S.; Shepherd, P. R.; Zannettino, A. C. W. NVP-BEZ235, a dual pan class I PI3 kinase and mTOR inhibitor, promotes osteogenic differentiation in human mesenchymal stromal cells. J. Bone Miner. Res. 2010, 25(10), 2126-2137.
135. Graupera, M.; Guillermet-Guibert, J.; Foukas, L. C.; Phng, L. K.; Cain, R. J.; Salpekar, A.; Pearce, W.; Meek, S.; Millan, J.; Cutillas, P. R.; Smith, A. J.; Ridley, A. J.; Ruhrberg, C.; Gerhardt, H.; Vanhaesebroeck, B. Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature. 2008, 453(7195), 662-666. (Pubitemid 351769296)
136. Zunder, E. R.; Knight, Z. A.; Houseman, B. T.; Apsel, B.; Shokat, K. M. Discovery of drug-resistant and drug-sensitizing mutations in the oncogenic PI3K isoform p110 alpha. Cancer Cell. 2008, 14(2), 180-192.
137. Kinkade, C. W.; Castillo-Martin, M.; Puzio-Kuter, A.; Yan, J.; Foster, T. H.; Gao, H.; Sun, Y.; Ouyang, X.; Gerald, W. L.; Cordon-Cardo, C.; Abate-Shen, C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormonerefractory prostate cancer in a preclinical mouse model. J. Clin. Invest. 2008, 118(9), 3051-3064.
138. Asenjo, A. B.; Sosa, H. A mobile kinesin-head intermediate during the ATP-waiting state. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(14), 5657-5662.
139. O'Brien, C.; Wallin, J. J.; Sampath, D.; GuhaThakurta, D.; Savage, H.; Punnoose, E. A.; Guan, J.; Berry, L.; Prior, W. W.; Amler, L. C.; Belvin, M.; Friedman, L. S.; Lackner, M. R. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin. Cancer Res. 2010, 16(14), 3670-3683.
140. Raynaud, F. I.; Eccles, S. A.; Patel, S.; Alix, S.; Box, G.; Chuckowree, I.; Folkes, A.; Gowan, S.; De Haven Brandon, A.; Di Stefano, F.; Hayes, A.; Henley, A. T.; Lensun, L.; Pergl-Wilson, G.; Robson, A.; Saghir, N.; Zhyvoloup, A.; McDonald, E.; Sheldrake, P.; Shuttleworth, S.; Valenti, M.; Wan, N. C.; Clarke, P. A.; Workman, P. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol. Cancer Ther. 2009, 8(7), 1725-1738.
141. Sutherlin, D. P.; Sampath, D.; Berry, M.; Castanedo, G.; Chang, Z.; Chuckowree, I.; Dotson, J.; Folkes, A.; Friedman, L.; Goldsmith, R.; Heffron, T.; Lee, L.; Lesnick, J.; Lewis, C.; Mathieu, S.; Nonomiya, J.; Olivero, A.; Pang, J.; Prior, W. W.; Salphati, L.; Sideris, S.; Tian, Q.; Tsui, V.; Wan, N. C.; Wang, S.; Wiesmann, C.; Wong, S.; Zhu, B. Y. Discovery of (thienopyrimidin-2-yl) aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer. J. Med. Chem. 2010, 53(3), 1086-1097.
142. Ihle, N. T.; Lemos, R., Jr.; Wipf, P.; Yacoub, A.; Mitchell, C.; Siwak, D.; Mills, G. B.; Dent, P.; Kirkpatrick, D. L.; Powis, G. Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res. 2009, 69(1), 143-150.
143. Buonamici, S.; Williams, J.; Morrissey, M.; Wang, A.; Guo, R.; Vattay, A.; Hsiao, K.; Yuan, J.; Green, J.; Ospina, B.; Yu, Q.; Ostrom, L.; Fordjour, P.; Anderson, D. L.; Monahan, J. E.; Kelleher, J. F.; Peukert, S.; Pan, S.; Wu, X.; Maira, S. M.; Garcia-Echeverria, C.; Briggs, K. J.; Watkins, D. N.; Yao, Y. M.; Lengauer, C.; Warmuth, M.; Sellers, W. R.; Dorsch, M. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci. Transl. Med. 2010, 2(51), 51ra70.
144. Lannutti, B. J.; Meadows, S. A.; Herman, S. E.; Kashishian, A.; Steiner, B.; Johnson, A. J.; Byrd, J. C.; Tyner, J. W.; Loriaux, M. M.; Deininger, M.; Druker, B. J.; Puri, K. D.; Ulrich, R. G.; Giese, N. A. CAL-101, a p110{delta} selective phosphatidylinositol-3-kinase inhibitor (PI3K) for the treatment of B cell malignancies inhibits PI3K signaling and cellular viability. Blood. 2010.
145. Bhatt, A. P.; Bhende, P. M.; Sin, S. H.; Roy, D.; Dittmer, D. P.; Damania, B. Dual inhibition of PI3K and mTOR inhibits autocrine and paracrine proliferative loops in PI3K/Akt/mTOR-addicted lymphomas. Blood. 2010, 115(22), 4455-4463.
146. Konstantinidou, G.; Bey, E. A.; Rabellino, A.; Schuster, K.; Maira, M. S.; Gazdar, A. F.; Amici, A.; Boothman, D. A.; Scaglioni, P. P. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009, 69(19), 7644-7652.
147. McMillin, D. W.; Ooi, M.; Delmore, J.; Negri, J.; Hayden, P.; Mitsiades, N.; Jakubikova, J.; Maira, S. M.; Garcia-Echeverria, C.; Schlossman, R.; Munshi, N. C.; Richardson, P. G.; Anderson, K. C.; Mitsiades, C. S. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009, 69(14), 5835-5842.
148. Lonial, S.; Harvey, R. D.; Francis, D.; Gul, E.; Jagannath, S.; Farag, S.; Hoth, D.; Frumento, R.; Garlich, J. R.; Trudel, S. Preliminary Results of a Phase I Study of the Pan-PI3 Kinase Inhibitor SF1126 in Patients with Relapsed and Refractory Myeloma. Blood. 2009, 114(22), 1492-1493.
149. Chiorean, E. G.; Mahadevan, D.; Harris, W. B.; Von Hoff, D. D.; Younger, A. E.; Rensvold, D. M.; Shelton, C. F.; Hennessy, B. T.; Garlich, J. R.; Ramanathan, R. K. Phase I evaluation of SF1126, a vascular targeted PI3K inhibitor, administered twice weekly IV in patients with refractory solid tumors. J. Clin. Oncol. 2009, 27(15), 2558.